Recruiting now
-
ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer
Phase 2 · 23 people · 1 site in China · Recruiting now
-
Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC
Phase 2 · 108 people · 1 site in China · Recruiting now
-
Tafolecimab Combined With Chemoimmunotherapy as Neoadjuvant Treatment for pMMR/MSS Locally Advanced Colon Cancer
Phase 2 · randomised · 70 people · 1 site in China · Recruiting now
-
Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Phase 2 · 120 people · 7 sites in 2 countries · Recruiting now
-
Local Methylene Blue Injection for Prevention of Anastomotic Leakage and Permanent Stoma After Low Anterior Resection for Rectal Cancer
Phase 2 · 26 people · 1 site in China · Recruiting now
-
Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer
Phase 3 · randomised · 430 people · 1 site in China · Recruiting now
-
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas
Phase 2 · 350 people · 11 sites in United States · Recruiting now
-
Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM
Phase 2 · 60 people · 1 site in China · Recruiting now